Clinical Trials Directory

Trials / Completed

CompletedNCT04040309

PRGF Effectiveness for Myofascial Pain Treatment in Masticatory Muscles

Plasma Rich in Growth Factors Effectiveness for Myofascial Pain Treatment in Masticatory Muscles: a Randomized Controlled Clinical Trial

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
50 (actual)
Sponsor
Lithuanian University of Health Sciences · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

The investigators set up a randomized controlled clinical trial to evaluate the effectiveness of plasma rich in growth factors (PRGF) injections into the masseter muscle trigger points for myofascial pain treatment. The investigators also seek to compare PRGF injections effectiveness with local anesthetic injections. Dry needling and local anesthetics injections release trigger point by disrupting the membranes of a tout band. However, the injected substance itself does not affect the pathophysiological mechanism of the trigger point. It is known that the platelets release growth factors who can enhance muscle regeneration processes and moreover reduce chronic pain. The investigators raised a hypothesis that PRGF injections into the trigger points in masseter muscle can be an effective treatment method for the myofascial pain.

Conditions

Interventions

TypeNameDescription
BIOLOGICALPRGF injectionPlasma rich in growth factors will be prepared following the protocol described by E. Anitua. 9 ml of patients venous blood will be taken into one tube with 3,8% sodium citrate used as an anticoagulant. The blood then will be centrifuged (PRGF Centrifuge System, Biotechnology Institute, Vitoria, Spain) at room temperature for 8 min at 1800 rpm. After centrifugation 1 ml of 2nd plasma fraction will be collected by using a pipet. To activate plasma 10% calcium chloride will be used immediately before injecting plasma into the trigger point in the masseter muscle.
DRUGLidocaine injection1 ml 2 % Lidocaine will be injected into the trigger point in the patient's masseter muscle.

Timeline

Start date
2019-05-10
Primary completion
2019-08-20
Completion
2019-08-25
First posted
2019-07-31
Last updated
2020-02-19

Locations

1 site across 1 country: Lithuania

Source: ClinicalTrials.gov record NCT04040309. Inclusion in this directory is not an endorsement.